2.03
Bioxcel Therapeutics Inc (BTAI) 最新ニュース
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates - MSN
BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BioXcel Therapeutics Advances Clinical Trials and Reduces Losses - TipRanks
BioXcel Therapeutics Inc. (BTAI) reports earnings - Quartz
BioXcel Therapeutics, Inc. SEC 10-K Report - TradingView
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics, Inc. Q4 Loss Declines - Nasdaq
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire
BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at RODMAN&RENSHAW - Defense World
BioXcel Therapeutics faces potential Nasdaq delisting By Investing.com - Investing.com Australia
BioXcel Therapeutics faces potential Nasdaq delisting - Investing.com
BIOXCEL THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
BioXcel Therapeutics reports progress in Phase 3 trial By Investing.com - Investing.com South Africa
BioXcel Therapeutics reports progress in Phase 3 trial - Investing.com India
Rodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy Recommendation - Nasdaq
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - Yahoo Finance
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial - Investing.com Australia
BioXcel Therapeutics boosts cash to $35M for Phase 3 trial By Investing.com - Investing.com South Africa
BioXcel Therapeutics: Topline Data Expected In H2 Of 2025 To Support Potential SNDA Submission For Label Expansion Of Igalmi In Home Setting - Marketscreener.com
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
BioXcel's $35M Funding Boost Powers Breakthrough At-Home Mental Health Treatment Trial - StockTitan
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week - MSN
10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey
BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - MSN
BioXcel Therapeutics reaches 33% enrollment in trial By Investing.com - Investing.com Australia
BioXcel Therapeutics reaches 33% enrollment in trial - Investing.com
BioXcel Therapeutics Reports 33% Enrollment in SERENITY At-Home Trial for IGALMI® Label Expansion, Topline Data Expected in 2025 - Nasdaq
BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial - TipRanks
BioXcel Therapeutics Announces 33% Enrollment in SERENITY - GlobeNewswire
Could This Be the First FDA-Approved At-Home Treatment for Bipolar and Schizophrenia Agitation? - StockTitan
BioXcel Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
BioXcel Therapeutics raises $14M in direct offering - Hartford Business Journal
Building Materials Stocks Q4 In Review: Sherwin-Williams (NYSE:SHW) Vs Peers - The Globe and Mail
Top Penny Stocks To Watch NowFebruary 28th - MarketBeat
Bioxcel Therapeutics Announces Closing Of $14 Million Registered Direct Offering -March 04, 2025 at 04:50 pm EST - Marketscreener.com
BioXcel Therapeutics, Inc. Closes $14 Million Registered Direct Offering of Common Stock and Warrants - Nasdaq
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering - GlobeNewswire
How Will BioXcel's $14M Offering Impact Shareholders? Key Details on BTAI's Latest Financing - StockTitan
3 Penny Stocks to Watch Now, 3/4/25 - TipRanks
Stock Market Update – BioXcel Therapeutics Stock Price Prediction 2025 - ldccbank
Sector Update: Health Care -March 03, 2025 at 03:51 pm EST - Marketscreener.com
BioXcel Therapeutics announces $14M registered direct offering - TipRanks
BioXcel Therapeutics, Inc. Secures $14 Million in Registered Direct Offering of Common Stock and Warrants - Nasdaq
BioXcel Therapeutics Announces $14 Million Registered Direct Offering - GlobeNewswire
大文字化:
|
ボリューム (24 時間):